24 October 2023
ECO Animal Health Group plc
(''ECO", the "Company" or the "ECO Group")
(AIM: EAH)
New USA and Canada label claim for Aivlosin®
ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that it has received a new US and Canadian label claim indication for Aivlosin® Water Soluble Granules ("WSG") in pigs.
Following years of research into the sow reproductive safety of Aivlosin® WSG, a new 'sow safety' indication has been approved by the US Food & Drug Administration (FDA). Prior to this approval, the label indication restricted WSG to be used only in the drinking water of swine intended for slaughter and not for use in lactating or pregnant females, or males and females intended for breeding.
The new label indication will be 'For use only in the drinking water of swine intended for slaughter and female swine intended for breeding. Not for use in male swine intended for breeding'.
Meanwhile, the Veterinary Drugs Directorate in Canada has also approved the removal of label statements regarding 'not for use in lactating or pregnant females and females intended for breeding'.
David Halls, CEO, commented: "We are pleased to have received this new label claim approved by the FDA which gives permission for ECO to sell into an additional market segment. This is testament to the continued market development of our products and these new claims and labels further enhance the safety message already used for Aivlosin in pigs."
For further information please contact:
| ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)
| 020 8447 8899
|
|
IFC Advisory Graham Herring Zach Cohen
|
020 3934 6630
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher |
020 7496 3000 |
|
Investec (Joint Broker) Gary Clarence Lydia Zychowska Carlo Spingardi |
020 7597 5970
|
| Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
